Annovis Bio Q2 net loss $0.44/share; cash $12.1M; AD & PD trial data positive

Annovis Bio, Inc.

2024-Q2 EPS reported -$1.52

Q2 2024 net loss $0.44 per share vs $1.07 YoY; operating expenses $7.8M (R&D $5.8M, G&A $2.0M).
Cash $4.0M at June 30, 2024; increased to $12.1M as of Aug 14 via warrant exercises and ELOC.
Phase 2/3 AD study: 3.3-point ADAS-Cog11 improvement vs 0.3 placebo; effective in APOE4 carriers; no ARIA.
Phase 3 PD study: improvements in MDS-UPDRS and cognition; halted cognitive decline in all patients.
New crystalline buntanetap patent filed; FDA OK for phase 3 with crystal form; US patent for TBI; team expanded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.